Stock XERS XERIS BIOPHARMA HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Xeris Biopharma Holdings, Inc.

Equities

XERS

US98422E1038

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
2.355 USD +0.64% Intraday chart for Xeris Biopharma Holdings, Inc. +11.61% +0.21%
Jul. 08 Xeris Biopharma Appoints John Shannon as CEO MT
Jul. 08 Xeris Biopharma Holdings, Inc. Announces CEO Changes CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Xeris Biopharma Appoints John Shannon as CEO
MT
Xeris Biopharma Announces CEO Succession Plan
BU
Xeris Biopharma Holdings, Inc. Announces CEO Changes
CI
Xeris Biopharma Holdings, Inc. Announces Executive Changes
CI
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(4)
AQ
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BU
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
BU
Sector Update: Health Care Stocks Higher in Afternoon Trading
MT
Xeris Biopharma Says Potential Levothyroxine Injection Preferred Over Oral Formulation; Shares Rise
MT
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
BU
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
CI
Xeris to Participate in the Jefferies Global Healthcare Conference
BU
Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M
MT
Xeris Biopharma: Q1 Earnings Snapshot
AQ
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
BU
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2024
CI
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product
MT
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XERS Stock
  4. News Xeris Biopharma Holdings, Inc.